Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone (NYSE:BSX)
· seekingalpha.com
Despite U.S. growth headwinds for WATCHMAN and electrophysiology, Boston Scientific delivered strong Q2 2026 results. Read why BSX stock is a Strong Buy.
Boston Scientific ( BSX ) appears to be a name that has been paying heavily for the extremely high expectations placed on it during 2024 and 2025. Over the last...